Therapeutic drug monitoring of tyrosine kinase inhibitors using dried blood microsamples
- Author
- Nick Verougstraete (UGent) , Veronique Stove (UGent) , Alain Verstraete (UGent) and Christophe Stove (UGent)
- Organization
- Abstract
- Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs) is not yet performed routinely in the standard care of oncology patients, although it offers a high potential to improve treatment outcome and minimize toxicity. TKIs are perfect candidates for TDM as they show a relatively small therapeutic window, a wide inter-patient variability in pharmacokinetics and a correlation between drug concentration and effect. Moreover, most of the available TKIs are susceptible to various drug-drug interactions and medication adherence can be checked by performing TDM. Plasma, obtained via traditional venous blood sampling, is the standard matrix for TDM of TKIs. However, the use of plasma poses some challenges related to sampling and stability. The use of dried blood microsamples can overcome these limitations. Collection of samples via finger-prick is minimally invasive and considered convenient and simple, enabling sampling by the patients themselves in their home-setting. The collection of small sample volumes is especially relevant for use in pediatric populations or in pharmacokinetic studies. Additionally, working with dried matrices improves compound stability, resulting in convenient and cost-effective transport and storage of the samples. In this review we focus on the different dried blood microsample-based methods that were used for the quantification of TKIs. Despite the many advantages associated with dried blood microsampling, quantitative analyses are also associated with some specific difficulties. Different methodological aspects of microsampling-based methods are discussed and applied to TDM of TKIs. We focus on sample preparation, analytics, internal standards, dilution of samples, external quality controls, dried blood spot specific validation parameters, stability and blood-to-plasma conversion methods. The various impacts of deviating hematocrit values on quantitative results are discussed in a separate section as this is a key issue and undoubtedly the most widely discussed issue in the analysis of dried blood microsamples. Lastly, the applicability and feasibility of performing TDM using microsamples in a real-life home-sampling context is discussed.
- Keywords
- tyrosine kinase inhibitors, therapeutic drug monitoring, microsampling, dried blood microsamples, oncology drugs, HEMATOCRIT BIAS, QUANTITATIVE-ANALYSIS, ALTERNATIVE TOOL, SPOT, IMATINIB, PLASMA, BIOANALYSIS, PREDICTION, NILOTINIB, PHARMACOKINETICS
Downloads
-
Publisher version.pdf
- full text (Published version)
- |
- open access
- |
- |
- 437.62 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8751261
- MLA
- Verougstraete, Nick, et al. “Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples.” FRONTIERS IN ONCOLOGY, vol. 12, 2022, doi:10.3389/fonc.2022.821807.
- APA
- Verougstraete, N., Stove, V., Verstraete, A., & Stove, C. (2022). Therapeutic drug monitoring of tyrosine kinase inhibitors using dried blood microsamples. FRONTIERS IN ONCOLOGY, 12. https://doi.org/10.3389/fonc.2022.821807
- Chicago author-date
- Verougstraete, Nick, Veronique Stove, Alain Verstraete, and Christophe Stove. 2022. “Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples.” FRONTIERS IN ONCOLOGY 12. https://doi.org/10.3389/fonc.2022.821807.
- Chicago author-date (all authors)
- Verougstraete, Nick, Veronique Stove, Alain Verstraete, and Christophe Stove. 2022. “Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples.” FRONTIERS IN ONCOLOGY 12. doi:10.3389/fonc.2022.821807.
- Vancouver
- 1.Verougstraete N, Stove V, Verstraete A, Stove C. Therapeutic drug monitoring of tyrosine kinase inhibitors using dried blood microsamples. FRONTIERS IN ONCOLOGY. 2022;12.
- IEEE
- [1]N. Verougstraete, V. Stove, A. Verstraete, and C. Stove, “Therapeutic drug monitoring of tyrosine kinase inhibitors using dried blood microsamples,” FRONTIERS IN ONCOLOGY, vol. 12, 2022.
@article{8751261, abstract = {{Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs) is not yet performed routinely in the standard care of oncology patients, although it offers a high potential to improve treatment outcome and minimize toxicity. TKIs are perfect candidates for TDM as they show a relatively small therapeutic window, a wide inter-patient variability in pharmacokinetics and a correlation between drug concentration and effect. Moreover, most of the available TKIs are susceptible to various drug-drug interactions and medication adherence can be checked by performing TDM. Plasma, obtained via traditional venous blood sampling, is the standard matrix for TDM of TKIs. However, the use of plasma poses some challenges related to sampling and stability. The use of dried blood microsamples can overcome these limitations. Collection of samples via finger-prick is minimally invasive and considered convenient and simple, enabling sampling by the patients themselves in their home-setting. The collection of small sample volumes is especially relevant for use in pediatric populations or in pharmacokinetic studies. Additionally, working with dried matrices improves compound stability, resulting in convenient and cost-effective transport and storage of the samples. In this review we focus on the different dried blood microsample-based methods that were used for the quantification of TKIs. Despite the many advantages associated with dried blood microsampling, quantitative analyses are also associated with some specific difficulties. Different methodological aspects of microsampling-based methods are discussed and applied to TDM of TKIs. We focus on sample preparation, analytics, internal standards, dilution of samples, external quality controls, dried blood spot specific validation parameters, stability and blood-to-plasma conversion methods. The various impacts of deviating hematocrit values on quantitative results are discussed in a separate section as this is a key issue and undoubtedly the most widely discussed issue in the analysis of dried blood microsamples. Lastly, the applicability and feasibility of performing TDM using microsamples in a real-life home-sampling context is discussed.}}, articleno = {{821807}}, author = {{Verougstraete, Nick and Stove, Veronique and Verstraete, Alain and Stove, Christophe}}, issn = {{2234-943X}}, journal = {{FRONTIERS IN ONCOLOGY}}, keywords = {{tyrosine kinase inhibitors,therapeutic drug monitoring,microsampling,dried blood microsamples,oncology drugs,HEMATOCRIT BIAS,QUANTITATIVE-ANALYSIS,ALTERNATIVE TOOL,SPOT,IMATINIB,PLASMA,BIOANALYSIS,PREDICTION,NILOTINIB,PHARMACOKINETICS}}, language = {{eng}}, pages = {{15}}, title = {{Therapeutic drug monitoring of tyrosine kinase inhibitors using dried blood microsamples}}, url = {{http://doi.org/10.3389/fonc.2022.821807}}, volume = {{12}}, year = {{2022}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: